Which laboratory tests should be ordered to evaluate hypercoagulability, including a basic coagulation screen, antiphospholipid antibody panel, and thrombophilia genetic and protein assays?

Laboratory Testing for Hypercoagulability

Order a comprehensive thrombophilia panel including Factor V Leiden, Prothrombin 20210A mutation, functional assays for antithrombin III, protein C, and protein S, along with a complete antiphospholipid antibody panel (lupus anticoagulant, anticardiolipin antibodies, and anti-β2-glycoprotein I antibodies). 1

Initial Basic Coagulation Screen

• Complete blood count (CBC) with platelet count to evaluate for thrombocytopenia or thrombocytosis 2, 1
• Prothrombin time (PT/INR) to assess the extrinsic coagulation pathway 2, 1
• Activated partial thromboplastin time (aPTT) to evaluate the intrinsic coagulation pathway 2, 1
• Chemistry panel to screen for underlying inflammatory disease or infectious processes 2

These basic tests should be performed first as they can identify acquired coagulopathies and establish baseline coagulation function before proceeding to specialized thrombophilia testing 2.

Genetic Thrombophilia Testing

Factor V Leiden (R506Q) mutation is the most common inherited thrombophilia and should be the primary genetic test ordered, as it accounts for >90% of hereditary activated protein C resistance 2, 1. This is easily detected through DNA testing and has high-quality evidence supporting its use 1.

Prothrombin 20210A variant testing should be performed simultaneously with Factor V Leiden, as it is the second most common inherited thrombophilia 1, 3. These two mutations together represent the most frequent genetic causes of hypercoagulability 3.

Functional Coagulation Protein Assays

• Antithrombin III functional assay to detect antithrombin deficiency 1
• Protein C functional assay to identify protein C deficiency 1
• Protein S functional assay to detect protein S deficiency 1

These protein deficiencies are too genetically heterogeneous for routine molecular genetic testing but can be reliably assessed through functional assays 1. They represent important causes of hereditary thrombophilia despite being less common than Factor V Leiden 1.

Antiphospholipid Antibody Panel

The antiphospholipid antibody panel is mandatory for comprehensive hypercoagulability evaluation, as these are the most common acquired blood protein defects causing thrombosis 4, 3.

Lupus Anticoagulant Testing

• Two parallel tests are required: dilute Russell's viper venom time (dRVVT) and lupus anticoagulant-sensitive aPTT 2
• Perform screening test followed by mixing and confirmatory tests for each positive screening result 2
• Do not test during anticoagulation if possible; if INR is 1.5-3.0, consider 1:1 dilution with normal pooled plasma, though interpretation remains difficult 2

The combination of dRVVT and aPTT detects lupus anticoagulant in the vast majority of cases, and omitting either test increases the risk of underdiagnosis in up to 55% of triple-positive patients 2. The aPTT alone is unreliable, being prolonged in only 40-50% of patients with lupus anticoagulant 4.

Anticardiolipin and Anti-β2-Glycoprotein I Antibodies

• Anticardiolipin antibodies (aCL) by ELISA for IgG, IgM, and IgA isotypes 2, 4
• Anti-β2-glycoprotein I antibodies (aβ2GPI) by ELISA for IgG, IgM, and IgA isotypes 2, 4
• Moderate-to-high titer thresholds are set at ≥40 Units for moderate and ≥80 Units for high titers 2

All three idiotypes (IgG, IgA, and IgM) should be assessed for both anticardiolipin and anti-β2GPI antibodies, as this comprehensive approach identifies the full spectrum of antiphospholipid syndrome 4. The presence of medium-high titers of aCL and aβ2GPI of the same isotype (most often IgG) in agreement with positive lupus anticoagulant identifies patients at highest risk for thrombosis 2.

Additional Testing to Consider

• Plasma homocysteine level rather than MTHFR genetic testing, as hyperhomocysteinemia interacts synergistically with Factor V Leiden 1, 3
• D-dimer may be useful for risk stratification in patients with previous thrombotic events, though it has poor specificity 2, 1

Critical Timing and Pre-Analytical Considerations

Avoid testing during acute thrombotic events or anticoagulation therapy whenever possible, as these conditions significantly interfere with test interpretation 2. Acute-phase reactants such as Factor VIII may be elevated during acute events, and full-dose heparin or warfarin therapy prolongs baseline clotting times 2.

Specific Timing Recommendations

• For warfarin therapy: Test 1-2 weeks after discontinuation or when INR <1.5 2
• For heparin therapy: Administer last dose of LMWH >12 hours before blood draw 2
• For direct oral anticoagulants (DOACs): Do not perform activated protein C resistance assays unless the assay is known to be insensitive to DOACs 2

Repeat testing is required for antiphospholipid antibodies: Persistent positivity must be confirmed on two or more occasions at least 12 weeks apart to meet diagnostic criteria for antiphospholipid syndrome 2. This distinguishes pathogenic antibodies from transient, clinically insignificant elevations 5.

Common Pitfalls to Avoid

• Do not test for MTHFR gene variants as routine thrombophilia workup; direct measurement of plasma homocysteine is more informative 1
• Do not test for Factor V R2 allele (H1299R) in routine thrombophilia evaluation 1
• Do not rely on aPTT alone to screen for lupus anticoagulant, as it is normal in 50-60% of cases 4
• Do not interpret protein C, protein S, or antithrombin results during acute thrombosis or anticoagulation, as these levels are affected by consumption, treatment, and acute-phase responses 2
• Do not stop at single-positive lupus anticoagulant without checking anticardiolipin and anti-β2GPI antibodies, as triple-positive patients have the highest thrombotic risk 2

Clinical Context for Testing

Testing should be prioritized in patients with:

• Idiopathic venous thromboembolism at age <50 years 3
• Recurrent thrombosis 3
• Thrombosis at unusual sites (cerebral venous thrombosis, mesenteric vein thrombosis) 2, 3
• Strong family history of thrombotic events 1, 3
• Recurrent unexplained pregnancy loss 4, 3

Venous thrombosis is multifactorial, and the presence of more than one genetic or acquired risk factor is common, justifying comprehensive panel testing rather than selective testing 1, 6.